In ulcerative colitis, does a mushy stool indicate a higher fecal calprotectin level?

Stool Consistency and Fecal Calprotectin in Ulcerative Colitis

Mushy stool alone does not reliably predict fecal calprotectin levels in ulcerative colitis—the relationship between symptoms and biomarkers is complex and often discordant.

Understanding the Symptom-Biomarker Relationship

The 2023 AGA guidelines explicitly address this disconnect between clinical symptoms (including stool consistency changes) and inflammatory biomarkers 1. The evidence demonstrates that:

• In symptomatic remission with elevated FC >150 mg/g: Patients may have no symptoms yet harbor active inflammation (very low certainty of evidence) 1
• In mild symptoms with normal FC <150 mg/g: Patients can have symptoms without corresponding inflammation (very low certainty of evidence) 1

The AGA recommends combining biomarkers with symptoms rather than relying on symptoms alone to inform treatment decisions 1.

Clinical Context Matters

Moderate to Severe Symptoms

If mushy stool accompanies frequent rectal bleeding and significantly increased stool frequency, then FC >150 mg/g reliably suggests moderate to severe endoscopic inflammation (low to moderate certainty) 1. In this high pretest probability scenario (85% prevalence of inflammation), elevated FC correlates well with active disease.

Mild Symptoms Only

If mushy stool represents only mild symptoms (slight increase in stool frequency without significant bleeding), the picture becomes murky:

• FC >150 mg/g may NOT indicate moderate to severe inflammation (very low certainty) 1
• FC <150 mg/g cannot rule out active inflammation (very low certainty) 1
• The AGA suggests proceeding directly to endoscopic assessment rather than relying on biomarkers alone 1

Disease Extent Influences Calprotectin Levels

Recent research demonstrates that disease extent significantly affects FC levels independent of inflammatory activity 2:

• In endoscopically active UC (MES ≥2): Proctitis shows median FC of 440 mg/kg vs. pancolitis at 1690 mg/kg (p=0.00005)
• In quiescent disease (MES ≤1): Pancolitis shows median FC of 85 mg/kg vs. proctitis at 24 mg/kg (p=0.00032)

However, FC remains reliable for detecting mucosal healing across all disease extents (AUC 0.878-0.915) 2.

Practical Algorithm

For a UC patient presenting with mushy stool:

1. Assess symptom severity comprehensively:

   • Rectal bleeding frequency (none, infrequent, frequent)
   • Stool frequency increase (mild vs. severe)
   • Recent treatment changes

2. If moderate-severe symptoms (frequent bleeding + significantly increased frequency):

   • Check FC; if >150 mg/g → confirms active inflammation, adjust treatment 1
   • Consider endoscopy if making major treatment decisions (starting/switching immunosuppression)

3. If mild symptoms only (mushy stool ± infrequent bleeding):

   • Proceed directly to endoscopy rather than FC testing 1
   • If patient prefers avoiding endoscopy: check FC and repeat in 3-6 months, but recognize normal FC doesn't exclude inflammation

4. If asymptomatic but concerned:

   • FC <150 mg/g reliably rules out active inflammation 1
   • FC <50 mg/g preferred if recently achieved remission (within 1-3 months) 1

Critical Pitfalls

• Don't assume mushy stool = elevated FC: The 2025 BSG guidelines note that clinical indices don't always correlate with active inflammation 3
• Don't ignore elevated FC in asymptomatic patients: 93.3% of UC patients with elevated FC have true inflammation 4
• Don't use FC alone for treatment escalation with mild symptoms: Very low certainty evidence supports endoscopic confirmation 1
• Consider non-IBD causes: FC elevates with C. difficile and other enteric infections—always exclude these 1

The 2026 research confirms that serum calprotectin cannot substitute for fecal calprotectin (weak correlation, ρ=0.21), so stick with stool testing 5.